# MRD Guidance Monitor: Weekly Digest

## Overview

Email digest sent Friday mornings with the week's most important MRD guidance updates.

---

## Design Principles

1. **Scannable** - Busy physicians, 2-minute read max
2. **Reference-focused** - Links to sources, not opinions
3. **Personalized** - Filter by cancer type preference
4. **No marketing** - Just curated references

---

## Email Structure

```
â”Œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”
â”‚  [OpenOnco Logo]                                            â”‚
â”‚                                                             â”‚
â”‚  MRD Guidance Monitor                                       â”‚
â”‚  Week of January 27, 2026                                   â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                             â”‚
â”‚  THIS WEEK: 3 guideline updates, 2 trial results,           â”‚
â”‚  1 new LCD                                                  â”‚
â”‚                                                             â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                             â”‚
â”‚  ðŸ“‹ GUIDELINE UPDATES                                       â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                      â”‚
â”‚                                                             â”‚
â”‚  NCCN Colon Cancer v2.2026                                  â”‚
â”‚  Updated January 24, 2026                                   â”‚
â”‚  MRD mention: Section MS-14, Category 2A                    â”‚
â”‚  â†’ View changes                                             â”‚
â”‚                                                             â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                             â”‚
â”‚  ðŸ”¬ TRIAL UPDATES                                           â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                      â”‚
â”‚                                                             â”‚
â”‚  CIRCULATE-Japan: Primary endpoint results published        â”‚
â”‚  Published: JCO, January 22, 2026                           â”‚
â”‚  Cancer: Colorectal                                         â”‚
â”‚  â†’ PubMed | NCT04120701                                     â”‚
â”‚                                                             â”‚
â”‚  PEGASUS: Status changed to "Active, not recruiting"        â”‚
â”‚  Updated: January 20, 2026                                  â”‚
â”‚  â†’ ClinicalTrials.gov                                       â”‚
â”‚                                                             â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                             â”‚
â”‚  ðŸ“„ KEY PUBLICATIONS                                        â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                      â”‚
â”‚                                                             â”‚
â”‚  "Consensus recommendations for ctDNA-guided adjuvant..."   â”‚
â”‚  Annals of Oncology, January 2026                           â”‚
â”‚  Cancer: Multi-solid tumor                                  â”‚
â”‚  â†’ PubMed                                                   â”‚
â”‚                                                             â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                             â”‚
â”‚  ðŸ’° COVERAGE & REGULATORY                                   â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€                                      â”‚
â”‚                                                             â”‚
â”‚  Novitas LCD L39291: Expanded ctDNA coverage                â”‚
â”‚  Effective: February 1, 2026                                â”‚
â”‚  â†’ View LCD                                                 â”‚
â”‚                                                             â”‚
â”œâ”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”¤
â”‚                                                             â”‚
â”‚  [Search Full Database]    [Manage Preferences]             â”‚
â”‚                                                             â”‚
â”‚  â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€  â”‚
â”‚  OpenOnco is a non-profit. No marketing, just references.   â”‚
â”‚  [Unsubscribe]                                              â”‚
â”‚                                                             â”‚
â””â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”€â”˜
```

---

## Section Priority

If limited space or few updates, prioritize in this order:

1. **Guideline updates** (NCCN, ASCO, ESMO) - always include
2. **Trial results** - practice-changing data
3. **Coverage changes** - affects what physicians can order
4. **Key publications** - consensus statements, major trials
5. **Trial status changes** - recruiting â†’ completed, etc.

---

## Personalization

Subscribers can filter by:
- **Cancer type**: Colorectal, Breast, Lung, Bladder, All
- **Content type**: Guidelines only, Trials only, Everything
- **Frequency**: Weekly (default), Biweekly, Monthly

If filtered, header shows: "Your digest: Colorectal cancer"

---

## Generation Logic

```javascript
// Pseudocode for digest generation

async function generateDigest(subscriber) {
  const weekStart = getLastFriday();
  const weekEnd = getThisFriday();
  
  // Get items from this week
  let items = await getGuidanceItems({
    dateRange: [weekStart, weekEnd],
    cancerTypes: subscriber.cancer_types || null,
    contentTypes: subscriber.content_types || null
  });
  
  // Get trial status changes
  let trialChanges = await getTrialStatusChanges({
    dateRange: [weekStart, weekEnd],
    cancerTypes: subscriber.cancer_types || null
  });
  
  // Group by section
  const sections = {
    guidelines: items.filter(i => i.evidence_type === 'guideline'),
    trials: items.filter(i => i.evidence_type === 'rct_results'),
    publications: items.filter(i => ['consensus', 'meta_analysis'].includes(i.evidence_type)),
    coverage: items.filter(i => i.source_type.startsWith('cms')),
    trialStatusChanges: trialChanges
  };
  
  // Render email
  return renderDigestEmail(sections, subscriber);
}
```

---

## Subject Lines

Format: `MRD Guidance: [highlight] + [count] more`

Examples:
- "MRD Guidance: NCCN Colon update + 4 more items"
- "MRD Guidance: CIRCULATE-Japan results published"
- "MRD Guidance: 6 new items this week"

If filtered:
- "MRD Guidance (Colorectal): NCCN update + 2 more"

---

## Technical Requirements

- **Sending**: Resend (existing integration)
- **Template**: React Email or MJML for responsive design
- **Scheduling**: Cron job Friday 7am ET
- **Tracking**: Open rate, click rate per section

---

## Future Enhancements

1. **Digest preview**: Web view before subscribing
2. **Custom alerts**: "Alert me when CIRCULATE results publish"
3. **RSS feed**: Alternative to email
4. **Slack integration**: For tumor boards
